Cor announces FDA Priority Review acceptance of sNDA for REZZAYO prophylaxis with PDUFA date in Q1 2027
CorMedix announced FDA acceptance of its supplemental NDA for REZZAYO (rezafungin) to prevent invasive fungal disease, granted Priority Review with a PDUFA target in Q1 2027. The submission is supported by positive Phase III ReSPECT results. If approved, Cor plans to start promotional efforts in H2 2027. According to the company, the FDA's acceptance accelerates the review timeline.
How this was made
The 30-second read
Why it matters
The regulatory milestone shortens the timeline to potential market launch, likely prompting a re‑rating by analysts.
Market read
Primary biotech news with direct price impact potential for CRMD.
What to watch
Potential competition from other antifungal agents and reimbursement uncertainties.
Background
CorMedix filed an 8‑K announcing FDA's acceptance of its supplemental NDA for REZZAYO, a fungicidal agent, and priority review status.
Ticker impact
FDA accepted CorMedix's sNDA for REZZAYO prophylaxis and granted Priority Review with a PDUFA target in Q1 2027.
likely upward pressure as investors price in earlier approval timeline.
Regulatory acceptance is a material catalyst for a biotech; market typically reacts positively to priority review grants.
Market effects
May boost sentiment for antifungal and prophylaxis biotech peers.
Limited to US biotech sector.
Minor, confined to specialty pharma investors.
Counterpoint
If the trial data later disappoint, the early review could be moot; caution on overpricing.
Key entities
- CompanyCorMedix Inc.
Biopharma developing rezafungin (REZZAYO).
- CompanyMundipharma
Partner submitting the sNDA.
